» Articles » PMID: 15147348

Differential Expression of CTLA-4 Among T Cell Subsets

Overview
Date 2004 May 19
PMID 15147348
Citations 80
Authors
Affiliations
Soon will be listed here.
Abstract

CTLA-4 (CD152), the CD28 homologue, is a costimulatory molecule with negative effects on T cell activation. In addition to its role in the termination of activation, CTLA-4 has been implicated in anergy induction and the function of regulatory cells. As an intracellular molecule, it must first relocate to the cell surface and be ligated, in order to inhibit activation. Although some studies have investigated CTLA-4 expression on CD4(+) T cells, evidence is lacking regarding the kinetics of expression, and expression on T cell subpopulations. We have investigated CTLA-4 kinetics on human purified peripheral CD4(+), naïve, memory, CD4(+)CD25(-), CD4(+)CD25(+) regulatory T cells, and T cell clones. Intracellular stores of CTLA-4 were shown to be very low in naïve T cells, whilst significant amounts were present in memory T cells and T cell clones. Cell surface CTLA-4 expression was then investigated on CD4(+)CD45RA(+) (naïve), CD4(+)CD45RO(+) (memory), CD4(+)CD25(-), and CD4(+)CD25(+) T cells. CD25 and CD45RO are both expressed by regulatory T cells. On naïve and CD4(+)CD25(-) T cells, CTLA-4 expression declined after four hours. In contrast, on memory and CD4(+)CD25(+) T cells, high levels of expression were maintained until at least 48 hours. In addition, significant CTLA-4 expression was observed on T cell clones following anergy induction, indicating the potential involvement of CTLA-4 also in this form of tolerance.

Citing Articles

Immune checkpoints and ncRNAs: pioneering immunotherapy approaches for hematological malignancies.

Anvari S, Nikbakht M, Vaezi M, Amini-Kafiabad S, Ahmadvand M Cancer Cell Int. 2024; 24(1):410.

PMID: 39702293 PMC: 11660508. DOI: 10.1186/s12935-024-03596-8.


How Co-Stimulatory/Inhibitory Molecules Vary Across Immune Cell Subtypes in the Severity of Systemic Lupus Erythematosus Compared to Controls.

Yu K, Lin W, Chen D Biomedicines. 2024; 12(11).

PMID: 39595011 PMC: 11591756. DOI: 10.3390/biomedicines12112444.


Comprehensive proteomic analysis of the differential expression of 62 proteins following intracortical microelectrode implantation.

Song S, Druschel L, Kasthuri N, Wang J, Conard J, Ricky Chan E Sci Rep. 2024; 14(1):17596.

PMID: 39080300 PMC: 11289480. DOI: 10.1038/s41598-024-68017-2.


Crosstalk between efferocytic myeloid cells and T-cells and its relevance to atherosclerosis.

Ngai D, Sukka S, Tabas I Front Immunol. 2024; 15:1403150.

PMID: 38873597 PMC: 11169609. DOI: 10.3389/fimmu.2024.1403150.


Diagnosing and Managing Uveitis Associated with Immune Checkpoint Inhibitors: A Review.

Zhang H, Houadj L, Wu K, Tran S Diagnostics (Basel). 2024; 14(3).

PMID: 38337852 PMC: 10855398. DOI: 10.3390/diagnostics14030336.


References
1.
Masteller E, Chuang E, Mullen A, Reiner S, Thompson C . Structural analysis of CTLA-4 function in vivo. J Immunol. 2000; 164(10):5319-27. DOI: 10.4049/jimmunol.164.10.5319. View

2.
Ling V, Wu P, Finnerty H, Sharpe A, GRAY G, Collins M . Complete sequence determination of the mouse and human CTLA4 gene loci: cross-species DNA sequence similarity beyond exon borders. Genomics. 1999; 60(3):341-55. DOI: 10.1006/geno.1999.5930. View

3.
Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N . Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med. 2000; 192(2):303-10. PMC: 2193248. DOI: 10.1084/jem.192.2.303. View

4.
Sansom D . CD28, CTLA-4 and their ligands: who does what and to whom?. Immunology. 2000; 101(2):169-77. PMC: 2327073. DOI: 10.1046/j.1365-2567.2000.00121.x. View

5.
da Rocha Dias S, Rudd C . CTLA-4 blockade of antigen-induced cell death. Blood. 2001; 97(4):1134-7. DOI: 10.1182/blood.v97.4.1134. View